A novel peptide encoded by circSRCAP confers resistance to enzalutamide by inhibiting the ubiquitin-dependent degradation of AR-V7 in castration-resistant prostate cancer
circSRCAP provides an epigenetic mechanism influencing AR-V7 stability and offers a promising therapeutic target for treating ENZ-resistant CRPC.
Authors
- Sufang Chu
- Chengsong Cao (ORCID: https://orcid.org/0000-0002-5243-2919)
- Suhua Qi (ORCID: https://orcid.org/0000-0002-1479-701X)
- Hongjun Guo
- Jin Bai (ORCID: https://orcid.org/0000-0003-1524-7893)
- Wendong Yang (ORCID: https://orcid.org/0009-0002-0241-9772)
- Qingxuan Wu
- Xiannan Meng
Institutions
- Xuzhou Medical College (CN)
- Xian Central Hospital (CN)
- Xuzhou Central Hospital (CN)
- First Hospital of Xi'an (CN)
Publication Details
- Journal
- Journal of Translational Medicine
- Published
- 2025-01-22
- DOI
- https://doi.org/10.1186/s12967-025-06115-z
- Citations
- 6
- Primary Topic
- Prostate Cancer Treatment and Research
- Type
- article
- Field-Weighted Citation Impact
- 9.11
Funders
- National Natural Science Foundation of China
- China Postdoctoral Science Foundation